Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy.
about
Conserved T cell receptor repertoire in primary and memory CD8 T cell responses to an acute viral infectionTherapeutic limitations in tumor-specific CD8+ memory T cell engraftmentAdoptive T cell therapy: Addressing challenges in cancer immunotherapyT cell avidity and tumor recognition: implications and therapeutic strategies.Use of recombinant lentivirus pseudotyped with vesicular stomatitis virus glycoprotein G for efficient generation of human anti-cancer chimeric T cells by transduction of human peripheral blood lymphocytes in vitro.Identifying Individual T Cell Receptors of Optimal Avidity for Tumor AntigensEnhancing Human Immunodeficiency Virus-Specific CD8(+) T Cell Responses with Heteroclitic Peptidesαβ TCR-mediated recognition: relevance to tumor-antigen discovery and cancer immunotherapyEffective T helper cell responses against retroviruses: are all clonotypes equal?Forward Vaccinology: CTL Targeting Based upon Physical Detection of HLA-Bound PeptidesThe kinematics of cytotoxic lymphocytes influence their ability to kill target cellsEfficient class II major histocompatibility complex presentation of endogenously synthesized hepatitis C virus core protein by Epstein-Barr virus-transformed B-lymphoblastoid cell lines to CD4(+) T cellsDNA immunization with hepatitis C virus (HCV) polycistronic genes or immunization by HCV DNA priming-recombinant canarypox virus boosting induces immune responses and protection from recombinant HCV-vaccinia virus infection in HLA-A2.1-transgenic miHigh Pro-Inflammatory Cytokine Secretion and Loss of High Avidity Cross-Reactive Cytotoxic T-Cells during the Course of Secondary Dengue Virus InfectionProphylactic DNA vaccine for hepatitis C virus (HCV) infection: HCV-specific cytotoxic T lymphocyte induction and protection from HCV-recombinant vaccinia infection in an HLA-A2.1 transgenic mouse model.The relationship of interacting immunological components in dengue pathogenesisEpitope-specific TCR repertoire diversity imparts no functional advantage on the CD8+ T cell response to cognate viral peptidesPrevention of Cytotoxic T Cell Escape Using a Heteroclitic Subdominant Viral T Cell DeterminantT-cell Receptor-optimized Peptide Skewing of the T-cell Repertoire Can Enhance Antigen TargetingStructural and Functional Correlates of Enhanced Antiviral Immunity Generated by Heteroclitic CD8 T Cell EpitopesHigh-Throughput Sequencing-Based Immune Repertoire Study during Infectious DiseaseHigh avidity cytotoxic T lymphocytes can be selected into the memory pool but they are exquisitely sensitive to functional impairmentCTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV controlAntigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy.Prospects for an influenza vaccine that induces cross-protective cytotoxic T lymphocytes.Conservation and diversity of influenza A H1N1 HLA-restricted T cell epitope candidates for epitope-based vaccines.Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positionsTCR-ligand koff rate correlates with the protective capacity of antigen-specific CD8+ T cells for adoptive transfer.CD4+ T cell subset differentiation and avidity setpoint are dictated by the interplay of cytokine and antigen mediated signalsHigh-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines.Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigenEpitope specificity is critical for high and moderate avidity cytotoxic T lymphocytes associated with control of viral load and clinical disease in horses with equine infectious anemia virus.Antitumor activity of immunotoxins with T-cell receptor-like specificity against human melanoma xenografts.Effective simian immunodeficiency virus-specific CD8+ T cells lack an easily detectable, shared characteristic.Low Antigen Dose in Adjuvant-Based Vaccination Selectively Induces CD4 T Cells with Enhanced Functional Avidity and Protective Efficacy.Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody.Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice.PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal.Transduction of human T cells with a novel T-cell receptor confers anti-HCV reactivity.Predominant clonal accumulation of CD8+ T cells with moderate avidity in the central nervous systems of Theiler's virus-infected C57BL/6 mice.
P2860
Q24657414-5073CCB0-F104-4C41-B7DA-642FEFFF7C26Q24794258-E7AF2CAA-28A9-42D9-A318-A681F4E43C40Q24805804-76083B1B-809F-492F-B0A4-C4C76FD5DEB5Q24815775-59DC4317-2989-431A-A1E7-FD99A40802AAQ25257888-D48DD8DA-3656-4158-A9D9-B9CEC31D5F2AQ26774669-1ED51BC7-B126-4603-8DAC-B5948A5AF795Q26800123-49690DF2-7EE1-400B-8640-25733AFA80D3Q26861133-85789248-8FA8-4091-AC50-70DE0DF403D9Q26995251-2BAC2E22-9C8F-4919-9E73-80ACCE86E101Q27008977-7D72560E-0DF7-4743-A719-03AF526A6B1AQ27337590-4B44E7A9-16A2-431E-AC9C-8EAD1B10A406Q27469572-04BA8750-676C-4548-9CB6-1E60FBE489E7Q27473069-706CD6C4-BF8F-4ED0-A8D5-5A1276A3523EQ27481682-ABA881BB-B685-4550-B453-27A5460E5D5FQ27488288-9684D060-DDB4-44B6-8A01-0C7EC11F3074Q27490496-67837A4B-6FC8-4B93-8642-D060D1E56951Q27649750-8A82B98F-31D7-4BEE-8454-49A90ADF6968Q27652640-0999E4C0-CB97-46A7-8143-37D481880CC0Q27672418-8DBC66E2-2C3F-49DE-A7CE-1385E4A8F5C3Q27683638-6B78FDF1-FDE2-42DF-91D1-A719E430E4E6Q28068214-D53158A0-B89A-4C70-AE22-F0FE1B62BD4CQ28729034-2E7FCE0F-5F19-4B38-B68B-793F635A78FAQ28740354-52C9BC07-DF31-4997-B3A4-9D9DC1B619CEQ30310231-23BADEB8-B6F3-4707-B490-0EF778029761Q30375714-ECAB670E-FE20-4924-8545-194354D7BF54Q30384675-C4D0EDF6-269B-4B87-8CDC-E6691D40560AQ30448796-8EF1322A-2214-4D19-9B86-C383C771E38BQ30576352-2EDEA83A-31C2-44C2-9CA2-428C2FFCC6D4Q31166277-0454CEB9-B400-408C-9002-47EB7644C194Q33303162-6BA9F4C4-5748-4EA0-AE5D-7E566C272DB0Q33322422-247D1386-40DF-4B9D-A0E6-5740DA4030A0Q33349793-2EF90EF1-B488-481E-BA60-E8B7EDCDC44DQ33357299-17DC3854-38BD-4441-96DD-E6111744CC5FQ33558348-3281BF0D-3B36-42BB-9C1E-D31C42D14A20Q33567970-7404E0D0-1D36-4696-8CAB-067973438043Q33581597-8F360479-60E0-4EFE-9748-5792709413C7Q33609436-6B8B916E-9876-43C3-B81E-FB91E148139EQ33644438-8BCE21F6-E4D7-4AE9-937B-4F460B0C1355Q33649735-DBC6BF91-2F5F-4228-9943-A43FA6EF90C0Q33676513-084992AD-5364-4D62-A014-B249D2BFF025
P2860
Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 1996
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Selective expansion of high- o ...... cy for adoptive immunotherapy.
@en
Selective expansion of high- o ...... cy for adoptive immunotherapy.
@nl
type
label
Selective expansion of high- o ...... cy for adoptive immunotherapy.
@en
Selective expansion of high- o ...... cy for adoptive immunotherapy.
@nl
prefLabel
Selective expansion of high- o ...... cy for adoptive immunotherapy.
@en
Selective expansion of high- o ...... cy for adoptive immunotherapy.
@nl
P2860
P921
P356
P1476
Selective expansion of high- o ...... acy for adoptive immunotherapy
@en
P2093
J A Berzofsky
M A Alexander-Miller
P2860
P304
P356
10.1073/PNAS.93.9.4102
P407
P577
1996-04-01T00:00:00Z